Kalaris Therapeutics
Quarterly Financials
| Values in thousands | 2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -11,350 | -8,753 | -37,269 | -5,151 |
EBIT | -12,256 | -10,354 | -37,849 | -4,187 |
Net Income | -11,350 | -10,196 | -38,084 | -5,650 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -12,539 | -7,441 | -4,327 | -3,971 |
Cash | 88,426 | 100,965 | 1,913 | |
Basic Shares | 18,701 | 4,053 | 18,702 | 18,702 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 |
|---|---|---|
Revenue | $0 | $0 |
EBITDA | -14,012 | -15,250 |
EBIT | -13,464 | -14,006 |
Net Income | -14,699 | -15,485 |
Net Change In Cash | 0 | 0 |
Free Cash Flow | -14,132 | -9,779 |
Cash | 3,169 | 3,059 |
Basic Shares | 18,702 | 18,702 |
Earnings Calls
| Quarter | EPS |
|---|---|
2025-06-30 | -$0.61 |
2025-03-31 | -$2.52 |
2024-12-31 | -$3.63 |
2024-09-30 | -$0.82 |
